As research advances, new discoveries may lead to the development of novel tools for use in clinical laboratories, aiding clinicians in their quest to provide patients with optimized treatment plans. Illumina is at the forefront of this movement, collaborating with researchers and healthcare experts in an effort to enable all laboratories to realize the benefits of next-generation sequencing.
The TruSight content sets are the first realization of Illumina's efforts in this area. Designed with recognized healthcare experts at leading institutions, the TruSight content sets comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
Researchers are rapidly advancing our understanding of disease-causing mutations and genetic dispositions. Illumina is committed to helping our customers deploy these new discoveries on next-generation sequencing technologies, and leverage them in a clinical environment. The ultimate goal is to make genomic information readily accessible for more informed, and hopefully better, patient care.
Innovation through Collaboration
Hear about our collaborative approach to developing TruSight content sets.
Transforming the Clinical Laboratory
Learn how TruSight content sets were developed to ensure maximum performance.
For Research Use Only.
Note regarding biomarker patents and other patents unique to specific uses of products.
Many Illumina products can be used to analyze a sample and detect the presence or absence of specific genomic variants within or across genes, nucleic acid sequences, or genomic regions, some of which, and their use in specific applications, may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.